Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
COVID-HIGIV · 1 trial · 1 indication
Number of subjects with AEs and severity of AEs up to 3 days post-dosing.
Number of subjects and severity of treatment emergent adverse events (TEAEs) that led to discontinuation or temporary suspension of IV infusion.
Number of subjects with TEAEs and SAEs up to 84 days post-dosing.
Number of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in all subjects reporting TEAEs/SAEs up to 84 days post-dosing.
The area under the concentration-time curve from time 0 to the last quantifiable concentration of SARS-CoV-2 binding IgG antibodies after COVID-HIGIV dose. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
Area under the concentration-time curve from time 0 to the last quantifiable concentration plus the additional area extrapolated to infinity of SARS-CoV-2 binding IgG antibodies after COVID-HIGIV dose. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
AUC from time 0 to 14 days (AUC0-14d) of SARS-CoV-2 binding IgG antibodies after COVID-HIGIV. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, and Day 15.
AUC from time 0 to 28 days of SARS-CoV-2 binding IgG antibodies after COVID-HIGIV dose. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, and Day 29.
The Cmax of SARS-CoV-2 binding IgG antibodies observed after COVID-HIGIV dose. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
Time at which Cmax occurs (Tmax) after COVID-HIGIV at each dose level .Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
The observed trough concentration of SARS-CoV-2 binding IgG antibodies 28 days after COVID-HIGIV dose. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, and Day 29.
The apparent terminal elimination half-life (T1/2) after dose of COVID-HIGIV. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
The systemic clearance (CL) of SARS-CoV-2 binding IgG antibodies after dose of COVID-HIGIV. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
The volume of distribution (Vz) of SARS-CoV-2 binding IgG antibodies after dose of COVID-HIGIV. Data for PK calculations was collected: pre-dose within 2 hrs prior to dosing, and post-dose at: 1 hr, 2 hrs, 4 hrs, 8 hrs, 12 hrs, 24 hrs, Day 4, Day 8, Day 15, Day 22, Day 29, Day 43, Day 57 and Day 85.
| Arm | Type | Description |
|---|---|---|
| COVID-HIGIV Dose Level 1 (100 mg/kg) | EXPERIMENTAL | Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 1 (100 mg/kg). |
| COVID-HIGIV Dose Level 2 (200 mg/kg) | EXPERIMENTAL | Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 2 (200 mg/kg). |
| COVID-HIGIV Dose Level 3 (400 mg/kg) | EXPERIMENTAL | Eligible subjects randomized to receive a single IV infusion of COVID-HIGIV dose level 3 (400 mg/kg). |
| Dose Placebo (saline) | PLACEBO_COMPARATOR | Eligible subjects randomized to receive a single IV infusion of saline placebo. |
| Name | Type | Description |
|---|---|---|
| COVID-HIGIV | BIOLOGICAL | COVID-HIGIV is a purified immunoglobulin G (IgG) liquid preparation containing antibodies (including neutralizing antibodies) to SARS-CoV-2. COVID-HIGIV will be administered via intravenous infusion. |
| Placebo (saline) | OTHER | The reference product is a liquid solution of normal saline (0.9% weight per unit volume (w/v) sodium chloride). Placebo will be administered via intravenous infusion. |
Inclusion Criteria: 1. Able and willing to provide written informed consent (voluntarily signed by the subject) prior to performing study procedures. 2. Females and males 18-60 years of age, inclusive. 3. Have a body mass index (BMI) less than or equal to 35.0 kg/m2. 4. Women who are either: A)...
COVID-HIGIV is an investigational monoclonal antibody being developed for COVID-19. It is designed to target the virus that causes COVID-19, though specific molecular targets have not been disclosed. The drug is currently in clinical development and has not been approved by regulatory authorities.
COVID-HIGIV is being developed by Emergent BioSolutions Inc. (ticker: EBS). The company is conducting clinical trials to evaluate the safety and pharmacokinetics of this investigational monoclonal antibody for COVID-19.
COVID-HIGIV is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains in early-stage clinical evaluation.
COVID-HIGIV has one completed Phase 1 clinical trial, NCT04661839, titled "A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults." The trial enrolled 28 healthy adult volunteers in the United States and was randomized, double-blind, and placebo-controlled.
No, COVID-HIGIV is not FDA approved. It is an investigational monoclonal antibody currently in Phase 1 clinical development. The completed Phase 1 trial evaluated safety and pharmacokinetics in healthy adults, but the drug has not yet received regulatory approval for any use.